多西他赛每周方案联合顺铂二线治疗治疗非小细胞肺癌

Clinical study on weekly administration of docetaxel for advanced non-small-cell lung cancer(NSCLC).

目的研究多西他赛每周方案联合顺铂二线治疗非小细胞肺癌（NSCLC）的疗效和毒性反应。方法48例晚期非小细胞肺癌患者，既往曾接受1个含铂方案治疗，采用多西他赛30mg／m^2，静脉滴注60min，第1、8、15d给药，顺铂40mg静脉滴注60rain，第1～3d，每28d为1周期。患者的行为状态评分（PS）均为ECOG≤2。结果48例患者均可评价，总共化疗周期数为189周期。1例完全缓解（CR）占2，1％，14例部分缓解（PR）占29．2％，有效率（ORR）为31．3％，中位生存时间为37周，1年生存率为33％，粒细胞减少与乏力为主要的毒性反应，其他的毒性反应为脱发和体液潴留。结论多西他赛30mg／m^2每周给药联合顺铂二线治疗NSCLC有确切的疗效且耐受性好。

Objective To study the efficacy and safety of docetaxel adiministrated weekly plus cisplatin in treatment of patients with advanced NSCLC. Methods Forty - eight patients with advanced NSCLC were treated by docetaxel at dosage of 30mg/m^2 on day 1, 8, 15 with intravenous infusion for 60 rain and cisplatin at a dose of 40mg on days 1 - 3. This therapeutic regimen was repeated every 28 days. Results The efficacy of treatment could be evaluated in 48 patients, the overall response rate （CR ＋ PR）was 31, 3 %. One of 48 assessable patients （2, 1% ） achieved complete response to treatment, 14 patients （29.2%） achieved part response to treatment. The median survival time of all patients was 37 weeks, and the 1 - year survival rate was 33%. The main acute side effects were fatigue, asthenia and neutropenia, and no other hematologic toxicity was observed, Conclusion Weekly docetaxel therapy is active and well tolerated by patients with advanced NSCLC.